Bookmark Kaumudi Online  Bookmark this site  Editor@Kaumudi  |  Marketing  Print Advt rates  |  Calendar 2012        Go!    
 
 
November 27, Thursday 2014 2:42 PM       
       HEADLINES: Manmohan in Kochi today                                              SC upholds death penalty of man for raping, killing 4 yr-old                                              No evidence found of murder, rape in Badaun sisters case                                              When Sharif walks for speech, Modi reads newspaper                                              FC Goa crush Kerala Blasters 3-0                                              Kaumudi Facebook
       BUSINESS Next Article: SBI mulls selling bad assets to ARCs in Jan-Mar quarter  
       Ranbaxy recalls over 64,000 bottles of generic Lipitor in US
 
         Posted on :22:10:56 Mar 8, 2014
   
A A
       Last edited on:22:10:56 Mar 8, 2014
         Tags: Ranbaxy, Lipitor in US
 

NEW DELHI: Drug major Ranbaxy Laboratories has recalled over 64,000 bottles of Atorvastatin calcium tablets, a generic version of cholesterol-lowering drug Lipitor, after a complaint of wrong dosage.

The Indian firm, which is reeling under regulatory action from the US Food and Drug Administration (USFDA), recalled the drug after a complaint by a pharmacist who discovered a 20 mg tablet inside a sealed bottle of Atorvastatin 10 mg tablets.

"Ranbaxy Pharmaceuticals is conducting a voluntary recall in the US limited to two lots of Atorvastatin calcium tablets, 10 mg manufactured in India which expire in May 2014," it said in a statement.

The company, majority owned by Japan's Daiichi Sankyo, said it recalled the tablets "because of a remote possibility of the presence of a 20 mg Atorvastatin calcium tablet in a 10 mg bottle."

"This is the basis of the voluntary recall," it added.

To date, Ranbaxy has not received any product complaints related to these batches, the company said.

"Other lot numbers, package sizes and strengths are not affected by this recall. The recall is being conducted at the retail level," it added.

Ranbaxy is withdrawing the lots out of abundant caution, keeping the safety of patients in mind and with full knowledge of the USFDA, it said.

In January, the USFDA prohibited Ranbaxy from producing and distributing drugs for the American market from its Toansa facility in Punjab.

The Toansa plant catered to over 70 per cent of Ranbaxy's requirement for raw material used in medicine formulations. Toansa was the fourth Ranbaxy plant banned by the USFDA.

In September, the USFDA imposed an import alert on Ranbaxy's Mohali plant in Punjab for violating good manufacturing norms.

Ranbaxy's key facilities at Paonta Sahib in Himachal Pradesh and Dewas in Madhya Pradesh have been under a US import alert since 2008.

A A
       BUSINESS
Next Article: SBI mulls selling bad assets to ARCs in Jan-Mar quarter
 
 
BUSINESS HEADLINES
Bear cartel suspected behind P-Notes bogey; trades under lens  
India '2nd most loved mkt' in Asia with $1.4 bn FII flow: HSBC  
China's AliBaba to invest more in India  
Banks collect Rs 6,000 cr in deposits from PMJDY accounts  
Sensex, Nifty touch new high, but close in red  
Markets at new highs on capital inflows, global cues  
Over dozen cos apply for public offers in FY'15  
Adani Power buys Avantha's 600 MW plant for Rs 4,200 crore  
India's strong leadership led to ending WTO impasse: Sitharaman  
Sensex, Nifty reach new peaks; banking, CG stocks lead rally  
GMR claims $803 mn for termination of Male Airport contract  
Future group acquires supermarket chain Nilgiris  
CAG seeks D6 audit for 2012-13, RIL agrees for 2013-14 too  
Tech Mahindra acquires US-based LCC for $240 mn  
Under Satya Nadella Microsoft emerges as world's 2nd top firm  
ICICI Bank Ltd to pay around Rs 60K for raising false charges  
Infosys names new CEO, CFO for BPO arm  
Shibulal, Gopalkrishnan launch biz incubator Axilor Ventures  
Retailers hobble online as e-commerce firms race ahead  
India may provide $1 billion loan for Adani Australia coal mine  
Seasonal decline in hiring activity in Oct: Naukri.com  
Oil prices likely to fall further: IEA  
Gold posts biggest single-day gain this year, surges by Rs 715  
Nadella effect: Microsoft surpasses Exxon, becomes world's second most valuable company  
Inflation drops to 5-year low of 1.77 pc in October  
 
How do you evaluate the past six months of Modi's rule?
Good
 
Average
 
Bad
 
 
 
Home Kerala India World Business Sports Sci&Tech Education Automobile CityNews Movies Environment Letters 
© Copyright keralakaumudi Online 2011  |  Reproduction in whole or in part without written permission is prohibited.
Head Office Address: Kaumudi Buildings, Pettah P.O, Trivandrum - 695024, India.
Online queries talk to Deepu Sasidharan, + 91 98472 38959 or Email deepu[at]kaumudi.com
Customer Service -Advertisement Disclaimer Statement   |  Copyright Policy